Brief: Innovent Biologics Says Pecondle Receives Approval From China's NMPA For Plaque Psoriasis
28/11/2025 08:50
Nov 28 (Reuters) - Innovent Biologics Inc 1801.HK: PECONDLE RECEIVES APPROVAL FROM CHINA'S NMPA FOR PLAQUE PSORIASIS Further company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis